We report on the process of adaptation into Spanish of the Rotterdam Symptom Check List (RSCL). The original version was translated and back-translated by professional bilingual translators. A quantitative rating method was used to select the items to include in the final Spanish version. Validity (
Validity of the Rotterdam symptom checklist in paediatric oncology
β Scribed by Eiser, C.; Havermans, T.; Craft, A.; Kernahan, J.
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 87 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
β¦ Synopsis
In order to determine the validity of the Rotterdam Symptom Checklist (RSC) for use with paediatric patients, a sample of 47 mothers with a child with acute lymphoblastic leukaemia (ALL) was asked to complete the RSC, the Play Performance Scale for Children PPSC and a measure of daily activity (HDI: Questionnaires were completed during routine outpatient visits. There were no effects of child age on number of symptoms reported. The physical symptom subscale of the RSC distinguished between children in terms of treatment status and number of hospitalisations. However, the psychological symptom subscale did not distinguish between these groups. Limitations of the scale for work with children are considered. These include difficulties experienced by patents in reporting psychological symptoms for their children, and the inappropriateness of a scale developed for adults to assess children. In the absence of other measures, the RSC can be used for children, but a more developmentally appropriate measures is needed.
π SIMILAR VOLUMES
## Abstract ## Objective The Patient Acceptable Symptom State (PASS) constitutes an absolute level of patient wellβbeing and represents an ambitious target for disease management. We explored contributors to PASS, validated the PASS concept, and assessed thresholds of selfβreported outcomes below
## Background: The siop nephroblastoma therapeutic protocols include a period of preoperative chemotherapy followed by nephrectomy and a period of postoperative chemotherapy. from the outset, identification of low-risk groups has been an aim of the siop nephroblastoma trials and studies. now that 9